Here is the design of a clinical trial:

Official Title: Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

Included conditions:
- Obesity
- HIV-1-infection

Study Armgroups:
- {'label': 'Semaglutide 0.25/0.5/1 mg plus standard of care', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Semaglutide Injectable Product', 'Behavioral: Standard of care']}
- {'label': 'Standard of care alone', 'type': 'OTHER', 'interventionNames': ['Behavioral: Standard of care']}

Interventions:
- {'type': 'DRUG', 'name': 'Semaglutide Injectable Product', 'description': 'Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.', 'armGroupLabels': ['Semaglutide 0.25/0.5/1 mg plus standard of care'], 'otherNames': ['Ozempic']}
- {'type': 'BEHAVIORAL', 'name': 'Standard of care', 'description': 'Diet and exercise advice for 40 weeks', 'armGroupLabels': ['Semaglutide 0.25/0.5/1 mg plus standard of care', 'Standard of care alone'], 'otherNames': ['Diet and exercise']}

Primary Outcomes:
- {'measure': 'Changes in total body weight (in Kg)', 'description': 'Between-group differences in percent change from baseline to week 28 in total body weight', 'timeFrame': '28 weeks'}

Please estimate the sample size based on the assumption: 
80% power, two-sided alpha of 0.05.
Sample size
        The target sample size for the SWIFT trial (the host trial) is 80 participants. Since this is a SWAT, the sample size will be decided by the SWIFT trial (the host trial), and no formal sample size calculation was performed. However, it is estimated that a difference of 15% (an effect size of 0.76) could be detected in DICCT scores with 80% power and a two-sided alpha of 0.05 with a sample size of 28 in each group. It is hoped that the results of this SWAT will ultimately be combined with the results from other similar SWAT in a meta-analysis.